ArticlePlastic and reconstructive surgery. Global open2025
Type IV Hypersensitivity Reaction to Dermabond Prineo in Plastic Surgery Patients: A Report of 4 Cases.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermabond Prineo, a 2-octyl cyanoacrylate-based skin closure system, is widely used in surgical procedures, but reports of adverse effects remain limited. This study aimed to report and analyze 4 cases of type IV hypersensitivity reactions to Dermabond in plastic surgery patients. The study was conducted in a private hospital in Cali, Colombia, between 2022 and 2024. Four patients who underwent reconstructive surgery and presented type IV hypersensitivity reaction after the use of Dermabond were included. Variables such as time of onset of symptoms, number of Dermabond applications, and postoperative management were considered. A literature review was performed for the analysis. All patients developed type IV hypersensitivity reactions after Dermabond application. Symptoms included erythema, pruritus, and other localized signs. These reactions improved significantly after the withdrawal of Dermabond and treatment with topical corticosteroids. All patients had been previously exposed to Dermabond in previous procedures. Dermabond reexposure in sensitized patients may induce type IV allergic reactions. Early identification and treatment of these reactions is crucial.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.